Patient-centred digital adherence technology for tuberculosis treatment outcomes: data from a pragmatic randomized controlled trial in Argentina

The dataset contains anonymized individual-level data from a pragmatic two-arm randomized controlled trial conducted in Argentina evaluating the effectiveness of a patient-centred digital adherence technology for tuberculosis (TB) treatment against usual practice for self-administered TB therapy under real-world conditions.
The study enrolled 555 patients newly diagnosed with drug-susceptible tuberculosis and compared an intervention integrating: an interactive smartphone application,direct communication with a treatment supporter, and INH adherence verification using a urine-based drug metabolite home test.
Participants were randomized in a 1:1 ratio to either the intervention arm or the control arm and followed to assess treatment success and loss to follow-up. Eligibility criteria included: age ≥16 years, newly diagnosed with drug-susceptible TB, regular access to and ability to operate a smart phone independently or with assistance. The TB-TST interactive digital adherence tool improved tuberculosis treatment outcomes. Treatment success was achieved in 82% compared to 74% and loss to follow-up occurred in 17% versus 24.4% in the intervention arm compared to the control arm in the ITT analysis. Greater benefit was observed among females, participants under 35 years and those more engaged with the app.
The dataset includes demographic characteristics, clinical baseline variables, randomization arm, adherence-related measures, and treatment outcomes. All data were fully anonymized prior to sharing. No direct identifiers are included.
This dataset supports the findings reported in the manuscript currently under peer review at The BMJ (Manuscript ID: BMJ-2025-086808.R1) and is intended to enable transparency, reproducibility, and secondary analyses.